Literature DB >> 1402023

Expression and characterization of a cDNA clone encoding an immunodominant surface glycoprotein of Pneumocystis carinii.

P J Haidaris1, T W Wright, F Gigliotti, C G Haidaris.   

Abstract

Most studies of antigens of Pneumocystis carinii have focused on an abundant, immunogenic 95- to 140-kDa surface glycoprotein referred to as gpA. Expression cloning of gpA from P. carinii obtained from ferrets resulted in isolation of colinear fragments of gpA cDNA encoding approximately 87 kDa of the core protein. Northern hybridization detected an abundant, single species of gpA-specific mRNA of 3600 nucleotides. Southern hybridization revealed gpA-specific bands only in P. carinii-infected lung genomic DNA, suggesting that gpA cDNA did not result from induction of a host lung gene. Antiserum raised against a fragment of recombinant gpA detected P. carinii cysts and isolated native P. carinii gpA, indicating retention of epitopes between the nonglycosylated recombinant gpA and glycosylated native gpA. The deduced amino acid sequence is hydrophilic and contains 12 potential N-linked glycosylation sites and 47 cysteine residues, consistent with the surface orientation of gpA on the organism and other known characteristics of the native molecule.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1402023     DOI: 10.1093/infdis/166.5.1113

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

Review 1.  Genetics of surface antigen expression in Pneumocystis carinii.

Authors:  J R Stringer; S P Keely
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  NF-kappaB activation during Rickettsia rickettsii infection of endothelial cells involves the activation of catalytic IkappaB kinases IKKalpha and IKKbeta and phosphorylation-proteolysis of the inhibitor protein IkappaBalpha.

Authors:  Dawn R Clifton; Elena Rydkina; Robert S Freeman; Sanjeev K Sahni
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Characterization of major surface glycoprotein genes of human Pneumocystis carinii and high-level expression of a conserved region.

Authors:  Q Mei; R E Turner; V Sorial; D Klivington; C W Angus; J A Kovacs
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

4.  CD86 (B7-2), but not CD80 (B7-1), expression in the epidermis of transgenic mice enhances the immunogenicity of primary cutaneous Candida albicans infections.

Authors:  A A Gaspari; R Burns; A Nasir; D Ramirez; R K Barth; C G Haidaris
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

5.  Induction of fibrinogen expression in the lung epithelium during Pneumocystis carinii pneumonia.

Authors:  P J Simpson-Haidaris; M A Courtney; T W Wright; R Goss; A Harmsen; F Gigliotti
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

6.  Cellular responses to a 55-kilodalton recombinant Pneumocystis carinii antigen.

Authors:  S A Theus; D W Sullivan; P D Walzer; A G Smulian
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Evidence for Proinflammatory β-1,6 Glucans in the Pneumocystis carinii Cell Wall.

Authors:  Theodore J Kottom; Deanne M Hebrink; Paige E Jenson; Gunnar Gudmundsson; Andrew H Limper
Journal:  Infect Immun       Date:  2015-04-27       Impact factor: 3.441

8.  Characterization of multiple unique cDNAs encoding the major surface glycoprotein of rat-derived Pneumocystis carinii.

Authors:  M J Linke; A G Smulian; J R Stringer; P D Walzer
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

9.  Expression of Pneumocystis jirovecii major surface glycoprotein in Saccharomyces cerevisiae.

Authors:  Geetha Kutty; Katherine J England; Joseph A Kovacs
Journal:  J Infect Dis       Date:  2013-03-26       Impact factor: 5.226

10.  Proliferative and cytokine responses to a major surface glycoprotein of Pneumocystis carinii.

Authors:  S A Theus; M J Linke; R P Andrews; P D Walzer
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.